JP2024520803A - ｕＰＡＲを標的とする抗原認識受容体及びその使用 - Google Patents

ｕＰＡＲを標的とする抗原認識受容体及びその使用 Download PDF

Info

Publication number
JP2024520803A
JP2024520803A JP2023575820A JP2023575820A JP2024520803A JP 2024520803 A JP2024520803 A JP 2024520803A JP 2023575820 A JP2023575820 A JP 2023575820A JP 2023575820 A JP2023575820 A JP 2023575820A JP 2024520803 A JP2024520803 A JP 2024520803A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520803A5 (enExample
Inventor
スコット ダブリュー． ロウ，
ミチェル サデライン，
ベガス， コリーナ アモル
ゼダ ジャン，
Original Assignee
メモリアル スローン ケタリング キャンサー センター
スローン － ケタリング・インスティテュート・フォー・キャンサー・リサーチ
メモリアル ホスピタル フォー キャンサー アンド アライド ディジージズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター, スローン － ケタリング・インスティテュート・フォー・キャンサー・リサーチ, メモリアル ホスピタル フォー キャンサー アンド アライド ディジージズ filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2024520803A publication Critical patent/JP2024520803A/ja
Publication of JP2024520803A5 publication Critical patent/JP2024520803A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2023575820A 2021-06-11 2022-06-10 ｕＰＡＲを標的とする抗原認識受容体及びその使用 Pending JP2024520803A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163209940P 2021-06-11 2021-06-11
US63/209,940 2021-06-11
PCT/US2022/032954 WO2022261403A1 (en) 2021-06-11 2022-06-10 Antigen recognizing receptors targeting upar and uses thereof

Publications (2)

Publication Number Publication Date
JP2024520803A true JP2024520803A (ja) 2024-05-24
JP2024520803A5 JP2024520803A5 (enExample) 2025-06-18

Family

ID=84425517

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575820A Pending JP2024520803A (ja) 2021-06-11 2022-06-10 ｕＰＡＲを標的とする抗原認識受容体及びその使用

Country Status (7)

Country Link
US (1) US20240123069A1 (enExample)
EP (1) EP4351602A4 (enExample)
JP (1) JP2024520803A (enExample)
CN (1) CN117693348A (enExample)
AU (1) AU2022287930A1 (enExample)
CA (1) CA3221368A1 (enExample)
WO (1) WO2022261403A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024520802A (ja) * 2021-06-11 2024-05-24 メモリアル スローン ケタリング キャンサー センター ｕＰＡＲを標的とする抗原認識受容体及びその使用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118240877A (zh) * 2024-03-15 2024-06-25 臻赫医药(杭州)有限公司 一种嵌合抗原受体纳米复合物及其制备方法和在制备抗衰老药物中的应用
WO2026086712A1 (en) * 2024-10-22 2026-04-30 Peking University Upar targeting chimeric antigen receptors and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170145106A1 (en) * 2015-11-25 2017-05-25 Renzhi Wang Chimeric antigen receptor hCD87-CAR and applications thereof
CN110343665A (zh) * 2019-05-05 2019-10-18 吉林大学 一种新型car-t细胞及其应用
WO2020160518A1 (en) * 2019-02-01 2020-08-06 Memorial Sloan Kettering Cancer Center Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker
JP2024520802A (ja) * 2021-06-11 2024-05-24 メモリアル スローン ケタリング キャンサー センター ｕＰＡＲを標的とする抗原認識受容体及びその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011100620A2 (en) * 2010-02-12 2011-08-18 The Regents Of The University Of California Upar binding agents and methods of use thereof
AU2012293720A1 (en) * 2011-08-05 2014-02-27 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Constitutively active uPAR variants and their use for the generation and isolation of inhibitory antibodies
EP3283522A1 (en) * 2015-04-17 2018-02-21 Spring Bioscience Corporation Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a
CA3215364A1 (en) * 2021-04-13 2022-10-20 Scott W. Lowe Car-t cells targeting upar and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170145106A1 (en) * 2015-11-25 2017-05-25 Renzhi Wang Chimeric antigen receptor hCD87-CAR and applications thereof
WO2020160518A1 (en) * 2019-02-01 2020-08-06 Memorial Sloan Kettering Cancer Center Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker
CN110343665A (zh) * 2019-05-05 2019-10-18 吉林大学 一种新型car-t细胞及其应用
JP2024520802A (ja) * 2021-06-11 2024-05-24 メモリアル スローン ケタリング キャンサー センター ｕＰＡＲを標的とする抗原認識受容体及びその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NATURE, vol. 583, JPN6026013281, 2020, pages 127 - 132, ISSN: 0005831993 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024520802A (ja) * 2021-06-11 2024-05-24 メモリアル スローン ケタリング キャンサー センター ｕＰＡＲを標的とする抗原認識受容体及びその使用

Also Published As

Publication number Publication date
EP4351602A4 (en) 2025-07-30
AU2022287930A9 (en) 2024-01-11
US20240123069A1 (en) 2024-04-18
CA3221368A1 (en) 2022-12-15
CN117693348A (zh) 2024-03-12
AU2022287930A1 (en) 2023-12-14
WO2022261403A1 (en) 2022-12-15
EP4351602A1 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
AU2020216486B2 (en) Senolytic car-T cells targeting uPAR, a cell surface and secreted senescence biomarker
AU2015357543B2 (en) Chimeric antigen receptors targeting Fc Receptor-like 5 and uses thereof
AU2022200052A1 (en) Chimeric antigen receptors targeting G-protein coupled receptor and uses thereof
JP2022105192A (ja) Ｂ細胞成熟抗原を標的化するキメラ抗原受容体およびその使用
US20240123069A1 (en) Antigen recognizing receptors targeting upar and uses thereof
JP2021516996A (ja) 生物学的に関連する直交サイトカイン／受容体対
US20210238258A1 (en) Chimeric orthogonal receptor proteins and methods of use
US20240131070A1 (en) Antigen recognizing receptors targeting upar and uses thereof
CN113454115B (zh) 靶向唾液酸化路易斯a的嵌合抗原受体及其用途
JP7776414B2 (ja) Ｃｄ３７１を標的にする抗原認識受容体およびその使用
CN117979976A (zh) 靶向upar的car-t细胞及其用途
US20250319131A1 (en) Tunable cytokine receptor signaling domains
US20260034241A1 (en) Compositions and methods for in vivo expression of chimeric antigen receptors
WO2025193972A1 (en) Methods of using il-15 signaling to enhance nk and nk-like t cell function against aml
WO2025085796A1 (en) Armored immunoresponsive cells targeting dll3 and uses thereof
EP4313130A1 (en) Antigen recognizing receptors targeting gd3 ganglioside and uses thereof
EA053037B1 (ru) Клетка, содержащая химерные рецепторы, нацеленные на adgre2 и/или clec12a, способ ее получения и ее применение, фармацевтическая композиция
HK40001773A (en) Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
BR122024009352A2 (pt) Receptor de antígeno quimérico (car), célula imunorresponsiva isolada e seus usos, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir uma célula imunorresponsiva que se liga ao antígeno de maturação de célula b (bcma), composição farmacêutica e kit para tratar uma neoplasia
BR112017011909B1 (pt) Receptor de antígeno quimérico (car), molécula de ácido nucleico, vetor, método para produzir uma célula imunorresponsiva que se liga ao antígeno de maturação de célula b (bcma), composição farmacêutica e kit para tratar um tumor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260402